Abstract:Background: Studies have reported that repeated annual vaccination may influence the effectiveness of the influenza vaccination in the current season. The mechanisms underlying these differences are unclear but might include focusing of the adaptive immune response to older strains. Methods: We established a 5-year randomized placebo-controlled trial of repeated influenza vaccination (Flublok, Sanofi Pasteur) in adults 18-45 years of age. Participants were randomized equally between five groups, with planned annual receipt of vaccination (V) or saline placebo (P) as follows: P-P-P-P-V, P-P-P-V-V, P-P-V-V-V, P-V-V-V-V, or V-V-V-V-V. Serum samples were collected each year just before vaccination and after 30 and 182 days. A subset of sera were tested by hemagglutination inhibition assays, focus reduction neutralization tests and enzyme-linked immunosorbent assays against vaccine strains. Results: From 23 October 2020 through 11 March 2021 we enrolled and randomized 447 adults. We selected sera from 95 participants at five timepoints from the first two study years for testing. Among vaccinated individuals, antibody titers increased between days 0 and 30 against each of the vaccine strains, with substantial increases for first-time vaccinees and smaller increases for repeat vaccinees, who had higher pre-vaccination titers in year 2. There were statistically significant reductions in the proportion of participants achieving a four-fold greater rise in antibody titer for the repeat vaccinees for A(H1N1), B/Victoria and B/Yamagata, but not for influenza A(H3N2). There were no statistically significant differences between groups in geometric mean titers at day 30 or the proportions of participants with antibody titers >=40 at day 30 for any of the vaccine strains. Conclusions: In the first two years, repeat vaccinees and first-time vaccinees had similar post-vaccination geometric mean titers to all four vaccine strains, indicative of similar levels of clinical protection. The vaccine strains of A(H1N1) and A(H3N2) were updated in year 2, providing an opportunity to explore antigenic distances between those strains in humans in subsequent years.

What problem does this paper attempt to address?

This paper aims to explore the impact of repeated influenza vaccination on the immune response, especially the antibody response against different influenza virus strains. The research background indicates that consecutive annual influenza vaccinations may affect the effectiveness of the current - season vaccine, but the mechanisms behind these differences are still unclear. One of the possible reasons is the "focusing" effect, that is, the adaptive immune response may focus on older virus strains, thereby reducing the protective effect against epidemic strains in some years. To explore this issue, researchers designed a five - year randomized controlled trial to study the immune response to the first or repeated influenza vaccinations in adults aged 18 to 45 years using the recombinant hemagglutinin quadrivalent influenza vaccine (Flublok®, Sanofi Pasteur). The study specifically focused on whether repeated vaccinations would produce specific changes in the immune response and how these changes would affect the effectiveness of the vaccine. Specifically, the main objective of the study was to measure the immunogenicity of the vaccine, determine the antibody titers against each vaccine strain by hemagglutination inhibition (HAI) test or focus - reduction neutralization test (FRNT), and compare the proportion of participants in each group who achieved the target antibody titer increase within 30 days after vaccination. In addition, the study also evaluated the geometric mean titer (GMT) ratios against each vaccine strain between different randomized groups on the 30th and 182nd days. These data are helpful for understanding the specific impact of repeated influenza vaccinations on the immune response.

Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial

Repeated Influenza Vaccination Induces Similar Immune Protection As First-Time Vaccination but with Differing Immune Responses

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial

Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines

Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection

Characterizing the dynamics of BCR repertoire from repeated influenza vaccination

Repeated vaccination with homologous influenza hemagglutinin broadens human antibody responses to unmatched flu viruses

Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years: Results and Experience From a Randomized, Double-Blind Trial

The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children

Intra-seasonal Antibody Repertoire Analysis of a Subject Immunized with an MF59®-adjuvanted Pandemic 2009 H1N1 Vaccine.

Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial

A potential platform for future vaccine trials identifies high incidence of symptomatic and asymptomatic influenza infection among children aged 6-23 months in South Africa

Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19

Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance

Neutralizing antibody responses against contemporary and future influenza A(H3N2) viruses in paradoxical clades elicited by repeated and single vaccinations

Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity

Immune Response Against Influenza in a Cohort of Repeatedly Vaccinated Adults During the 2017/2018 and 2018/2019 Seasons

Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses

Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children

Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations